Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

BACKGROUND: Many clinical studies have shown that patients with non-small cell lung carcinoma (NSCLC) can benefit from immune checkpoint inhibitor (ICI) therapy; however, PD-L1 and tumor mutation burden (TMB), which are recommended by the NCCN guidelines, are still insufficient in predicting the res...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Liuning, Lu, Guojie, Liu, Yang, Gong, Longlong, Zheng, Xue, Zheng, Hongbo, Gu, Weiguang, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213070/
https://www.ncbi.nlm.nih.gov/pubmed/34150625
http://dx.doi.org/10.3389/fonc.2021.658690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213070/
https://www.ncbi.nlm.nih.gov/pubmed/34150625
http://dx.doi.org/10.3389/fonc.2021.658690

Ejemplares similares